Jaqueline Carvalho de Oliveira

Prof. Jaqueline Carvalho de Oliveira

Federal University of Parana - Brazil

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2018 in The Journal of Gene Medicine
Verified
Journal Article
Closed access
PDF file
Jaqueline Carvalho de OliveiraJaqueline Carvalho de Oliveira
Jaqueline Carvalho de Oliveira
LOLuana Caroline Oliveira
Luana Caroline Oliveira
CMCarolina Mathias
Carolina Mathias
GPGabrielle Araújo Pedroso
Gabrielle Araújo Pedroso
DLDebora Souza Lemos
Debora Souza Lemos
Daniela GradiaDaniela Gradia
Daniela Gradia

1 March 2012 in Leukemia Research
Verified
Journal Article
Closed access
Jaqueline Carvalho de OliveiraJaqueline Carvalho de Oliveira
Jaqueline Carvalho de Oliveira
CSCarlos Alberto Scrideli
Carlos Alberto Scrideli
MBMaría Sol Brassesco
María Sol Brassesco
AMAndressa Gois Morales
Andressa Gois Morales
JPJulia Pezuk
Julia Pezuk
LTLuiz Gonzaga Tone
Luiz Gonzaga Tone

26 July 2013 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
JPJulia Pezuk
Julia Pezuk
MBMaría Sol Brassesco
María Sol Brassesco
AMA G Morales
A G Morales
Jaqueline Carvalho de OliveiraJaqueline Carvalho de Oliveira
Jaqueline Carvalho de Oliveira
RQR G de Paula Queiroz
R G de Paula Queiroz
LTLuiz Gonzaga Tone
Luiz Gonzaga Tone
Glioblastoma (GBM) is one of the most aggressive central nervous system tumors with a patient’s median survival of <1 year. Polo-like kinases (PLKs) are a family of serine/threonine kinases that have key roles in cell cycle control and DNA-damage response. We evaluated PLK1, 2, 3 and 4 gene expression in 8 GBM cell lines and 17 tumor samples, and analyzed the effect of the PLK1 inhibition on SF188 and T98G GBM cell lines and 13 primary cultures. Our data showed PLK1 overexpression and a variable altered expression of PLK2, 3 and 4 genes in GBM tumor samples and cell lines. Treatments with nanomolar concentrations of BI 2536, BI 6727, GW843682X or GSK461364 caused a significant decrease in GBM cells proliferation. Colony formation was also found to be inhibited (P<0.05), whereas apoptosis rate and mitotic index were significantly increased (P<0.05) after PLK1 inhibition in both GBM cell lines. Cell cycle analysis showed an arrest at G2 (P<0.05) and cell invasion was also decreased after PLK1 inhibition. Furthermore, simultaneous combinations of BI 2536 and temozolomide produced synergistic effects for both the cell lines after 48 h of treatment. Our findings suggest that PLK1 might be a promising target for the treatment of GBMs.

11 May 2018 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
GCGabriel Adelman Cipolla
Gabriel Adelman Cipolla
Jaqueline Carvalho de OliveiraJaqueline Carvalho de Oliveira
Jaqueline Carvalho de Oliveira
ASAmanda Salviano-Silva
Amanda Salviano-Silva
SLSara C. Lobo-Alves
Sara C. Lobo-Alves
DLDebora S. Lemos
Debora S. Lemos
Daniela GradiaDaniela Gradia
Daniela Gradia
Multifactorial diseases such as cancer, cardiovascular conditions and neurological, immunological and metabolic disorders are a group of diseases caused by the combination of genetic and environmental factors. High-throughput RNA sequencing (RNA-seq) technologies have revealed that less than 2% of the genome corresponds to protein-coding genes, although most of the human genome is transcribed. The other transcripts include a large variety of non-coding RNAs (ncRNAs), and the continuous generation of RNA-seq data shows that ncRNAs are strongly deregulated and may be important players in pathological processes. A specific class of ncRNAs, the long non-coding RNAs (lncRNAs), has been intensively studied in human diseases. For clinical purposes, lncRNAs may have advantages mainly because of their specificity and differential expression patterns, as well as their ideal qualities for diagnosis and therapeutics. Multifactorial diseases are the major cause of death worldwide and many aspects of their development are not fully understood. Recent data about lncRNAs has improved our knowledge and helped risk assessment and prognosis of these pathologies. This review summarizes the involvement of some lncRNAs in the most common multifactorial diseases, with a focus on those with published functional data.

31 May 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
CMCarolina Mathias
Carolina Mathias
JMJoão Carlos Degraf Muzzi
João Carlos Degraf Muzzi
BABruna Borba Antunes
Bruna Borba Antunes
Daniela GradiaDaniela Gradia
Daniela Gradia
MCMauro A. A. Castro
Mauro A. A. Castro
Jaqueline Carvalho de OliveiraJaqueline Carvalho de Oliveira
Jaqueline Carvalho de Oliveira
Breast cancer (BRCA) is the most leading cause of cancer worldwide. It is a heterogeneous disease with at least five molecular subtypes including luminal A, luminal B, basal-like, HER2-enriched, and normal-like. These five molecular subtypes are usually stratified according to their mRNA profile patterns; however, ncRNAs are increasingly being used for this purpose. Among the ncRNAs class, the long non-coding RNAs (lncRNAs) are molecules with more than 200 nucleotides with versatile regulatory roles; and high tissue-specific expression profiles. The heterogeneity of BRCA can also be reflected regarding tumor microenvironment immune cells composition, which can directly impact a patient’s prognosis and therapy response. Using BRCA immunogenomics data from a previous study, we propose here a bioinformatics approach to include lncRNAs complexity in BRCA molecular and immune subtype. RNA-seq data from The Cancer Genome Atlas (TCGA) BRCA cohort was analyzed, and signal-to-noise ratio metrics were applied to create these subtype-specific signatures. Five immune-related signatures were generated with approximately ten specific lncRNAs, which were then functionally analyzed using GSEA enrichment and survival analysis. We highlighted here some lncRNAs in each subtype. LINC01871 is related to immune response activation and favorable overall survival in basal-like samples; EBLN3P is related to immune response suppression and progression in luminal B, MEG3, XXYLT1-AS2, and LINC02613 were related with immune response activation in luminal A, HER2-enriched and normal-like subtypes, respectively. In this way, we emphasize the need to know better the role of lncRNAs as regulators of immune response to provide new perspectives regarding diagnosis, prognosis and therapeutical targets in BRCA molecular subtypes.

7 January 2019 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
CMCarolina Mathias
Carolina Mathias
EZErika Zambalde
Erika Zambalde
PRPhilip Rask
Philip Rask
Daniela GradiaDaniela Gradia
Daniela Gradia
Jaqueline Carvalho de OliveiraJaqueline Carvalho de Oliveira
Jaqueline Carvalho de Oliveira